Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Test to Predict Acute Myeloid Leukemia

October 24, 2011 12:17 pm | News | Comments

Abbott received clearance from the U.S. Food and Drug Administration for an in vitro test to aid in determining the prognosis of acute myeloid leukemia patients.

TOPICS:

Clavis Pharma Study Completion

October 24, 2011 12:11 pm | News | Comments

Clavis Pharma announces the cut-off level for defining hENT1 low verse high expression for assessing the results from the LEAP trial with CP-4126 in pancreatic cancer patients.

TOPICS:

Non-Hodgkin Lymphoma Risk Factors Include Diet

October 24, 2011 12:04 pm | News | Comments

Young adulthood body weight and diet appear to be associated with the risk for non-Hodgkin lymphoma.

TOPICS:
Advertisement

RNA-Seq Solutions

October 24, 2011 7:56 am | Product Releases | Comments

Appistry, Inc. announced the release of a series of advanced RNA-Seq solutions for the rapid analysis of sequencing data generated by this emerging technology.

TOPICS:

Dissolution Apparatus

October 24, 2011 7:48 am | Product Releases | Comments

Agilent Technologies Inc. has introduced the 709-DS Dissolution Apparatus, which features a bath-free design that provides an unobstructed view of the dissolution vessel.

TOPICS:

Amgen Working with Freeslate on Protein Drugs

October 24, 2011 7:33 am | News | Comments

Freeslate, Inc. announced that Amgen, Inc. has entered into a collaborative relationship with the company to leverage Freeslate solutions in addressing aggregation and particulation in protein drug products.

TOPICS:

DFMO May Become Skin Cancer Treatment

October 24, 2011 7:28 am | News | Comments

Researchers found that DFMO, or ?-difluoromethylornithine, still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug.

TOPICS:

BG-12 Performs Well in Late-Stage Trial

October 24, 2011 7:25 am | News | Comments

Biogen Idec announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 in people with relapsing-remitting multiple sclerosis.

TOPICS:
Advertisement

CHMP Issues Positive Opinion on Bronchitol

October 24, 2011 7:19 am | News | Comments

Pharmaceutical company Pharmaxis announced the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a Marketing Authorization for Bronchitol, a cystic fibrosis treatment.

TOPICS:

Amag-Allos Deal Called Off

October 24, 2011 7:07 am | News | Comments

Amag Pharmaceuticals Inc. will not acquire lymphoma drug maker Allos Therapeutics Inc., as Amag's shareholders voted down the deal. Amag said its shareholders voted against issuing new stock.

TOPICS:

Humalog on Par with Older Treatments

October 24, 2011 7:05 am | News | Comments

Halozyme Therapeutics Inc. said that two clinical trials showed its "ultrafast" insulin worked as well as an older insulin replacement for patients with both type 1 and type 2 diabetes.

TOPICS:

Biogen-Abbott MS Drug Outperforms Placebo

October 24, 2011 6:52 am | News | Comments

Biogen Idec and Abbott Laboratories said a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing relapse of symptoms of the inflammatory disease.

TOPICS:

Development of Autistic Brains Versus Healthy Brains

October 21, 2011 12:04 pm | News | Comments

Researchers at UCLA have found a possible explanation for why autistic children act and think differently than their peers.

TOPICS:

Lisdexamfetamine Dimesylate Proves Effective for ADHD

October 21, 2011 12:00 pm | News | Comments

Shire announced positive results of a European Phase 3 study of once-daily lisdexamfetamine dimesylate in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

TOPICS:

Target Identified To Decrease Triglycerides, Increase Cholesterol

October 21, 2011 11:32 am | News | Comments

Researchers announce findings that show the inhibition of both microRNA-33a and microRNA-33b with chemically modified anti-miR oligonucleotides suppress triglyceride levels and cause an increase in high density lipoprotein cholesterol.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading